Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the
study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and
second, to explore neurobiological mechanisms of action of guanfacine.
Phase:
Phase 1
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development